CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, and other key ...
Pharmabiz

US FDA clears CStone’s IND application for novel trispecific antibody CS2009 to advance into phase II trial

US FDA clears CStone’s IND application for novel trispecific antibody CS2009 to advance into phase II trial: Suzhou, China Tuesday, February 17, 2026, 11:00 Hrs [IST] CStone Pha ...

CTLA-4 Inhibitors Competitive Landscape Research Report 2026: Comprehensive Insights About 40+ Companies and 50+ Drugs by Product Type, Stage, Route of Administration, and ...

The CTLA-4 inhibitors market offers promising opportunities in cancer immunotherapy, with over 40 companies developing 50+ drugs globally. Key opportunities include leveraging synergistic combinations ...
Seeking Alpha

Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia ...

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and ...
Seeking Alpha

Xilio Therapeutics to Present Updated Phase 2 Data for Vilastobart, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Combination with Atezolizumab in Patients with Microsatellite ...

Session Date and Time: Saturday, May 31, from 9:00 a.m. to 12:00 p.m. CDT About Vilastobart and the Phase 1/2 Combination Clinical Trial Vilastobart is an investigational tumor-activated, Fc-enhanced, ...

CStone Pharmaceuticals: CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial

CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate ...